Adrenomedullin
Overview
Adrenomedullin is a 52-amino acid peptide hormone produced by vascular endothelial and smooth muscle cells with potent vasodilatory and natriuretic properties. It signals through calcitonin receptor-like receptor complexed with receptor activity-modifying proteins, increasing cyclic AMP to promote vasodilation, angiogenesis, and anti-inflammatory effects. Adrenomedullin also modulates vascular permeability and exhibits cardioprotective and renoprotective actions.
Key Research Findings
Plasma adrenomedullin levels correlate with severity and prognosis in heart failure and sepsis, with biomarker studies validating its prognostic utility. Synthetic analogues and stabilized forms are under investigation, though no adrenomedullin-based therapeutic has achieved regulatory approval for cardiovascular indications to date.
Intravenous
Investigational
Interested in Adrenomedullin?
Find a verified provider experienced with Adrenomedullin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Adrenomedullin ProviderRelated Peptides
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets.
Nesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.
Angiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release. Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors.
Serelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked by disulfide bonds. It acts via the relaxin family peptide receptor 1 (RXFP1) to promote vasodilation, inhibit fibrosis, and modulate hemodynamics. The therapeutic rationale targets acute heart failure by improving renal perfusion and reducing vascular resistance.